D000813Chemicals & DrugsD02.065.199D02.092.146.11328460.961578Anilidesprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson29550566Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJEuropean journal of cancer (Oxford, England : 1990)Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018 05; 94:115-125.Eur J Cancer2018-03-20T00:00:002018Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.30827746MartĂnez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LCThe Lancet. OncologyCabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019 04; 20(4):581-590.Lancet Oncol2019-02-28T00:00:002019Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.31992589Dhani NC, Hirte HW, Wang L, Burnier JV, Jain A, Butler MO, Welch S, Fleming GF, Hurteau J, Matsuo K, Matei D, Jimenez W, Johnston C, Cristea M, Tonkin K, Ghatage P, Lheureux S, Mehta A, Quintos J, Tan Q, Kamel-Reid S, Ludkovski O, Tsao MS, Wright JJ, Oza AMClinical cancer research : an official journal of the American Association for Cancer ResearchPhase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clin Cancer Res. 2020 06 01; 26(11):2477-2486.Clin Cancer Res2020-01-28T00:00:002020Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86).33277441Chaudagar KK, Landon-Brace N, Solanki A, Hieromnimon HM, Hegermiller E, Li W, Shao Y, Joseph J, Wilkins DJ, Bynoe KM, Li XL, Clohessy JG, Ullas S, Karp JM, Patnaik AMolecular cancer therapeuticsCabozantinib Unlocks Efficient In Vivo Targeted Delivery of Neutrophil-Loaded Nanoparticles into Murine Prostate Tumors. Mol Cancer Ther. 2021 02; 20(2):438-449.Mol Cancer Ther2020-12-04T00:00:002020Cabozantinib Unlocks Efficient In Vivo Targeted Delivery of Neutrophil-Loaded Nanoparticles into Murine Prostate Tumors.Medicine-Hematology and OncologyObstetrics and Gynecology-Gynecologic Oncology32645282Apolo AB, Nadal R, Tomita Y, Davarpanah NN, Cordes LM, Steinberg SM, Cao L, Parnes HL, Costello R, Merino MJ, Folio LR, Lindenberg L, Raffeld M, Lin J, Lee MJ, Lee S, Alarcon SV, Yuno A, Dawson NA, Allette K, Roy A, De Silva D, Lee MM, Sissung TM, Figg WD, Agarwal PK, Wright JJ, Ning YM, Gulley JL, Dahut WL, Bottaro DP, Trepel JBThe Lancet. OncologyCabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. Lancet Oncol. 2020 08; 21(8):1099-1109.Lancet Oncol2020-07-06T00:00:002020Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.1.353940.031143728research area of0.7948310.066817638subject area forhttps://obgyn.uchicago.edu/page/section-gynecologic-oncologyGynecologic Oncology Section - Univ. of Chicagohttps://obgyn.uchicago.edu/Univ. of Chicago OB&GYNhttp://obg.bsd.uchicago.edu/FacultyResearch/lengyellab.htmOvarian Cancer Laboratory in Chicagohttps://www.uchicagomedicine.org/find-a-physician/physician/ernst-lengyelClinical Profilehttps://www.uchicagomedicine.org/conditions-services/obgyn/specialtyOB&GYN Clinical Patient informationMedicineUniversity of ChicagoScott E.EggenerScott E. Eggener41.78927490000000-87.601250000000001156Eggener, Scott E.ProfessorEzraCohenEzra Cohen41.78927490000000-87.601250000000001350Cohen, EzraASSOCIATE PROFESSORErnst RobertLengyel0m5sBaYMHOD5hHlsaUXv9Gq0+s+oErnst Robert Lengyel41.78927490000000-87.601250000000001942Lengyel, Ernst RobertProfessorHedyKindler32lgBaUZHP75hHlsaUXv9Gq0+s+oHedy Kindler41.78927490000000-87.601250000000002499Kindler, HedyProfessortrue1ASSOCIATE PROFESSORASSOCIATE PROFESSORtrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessorSurgery-UrologyAkashPatnaikAkash Patnaik0.000000000000000.000000000000003310Patnaik, AkashAssociate Professor